12:00 AM
 | 
Jun 15, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Protectan: Phase I data

Data from an ascending-dose, U.S. Phase I trial in 50 healthy volunteers showed that Protectan (CBLB502) was well tolerated and biomarker results corresponded with activity in...

Read the full 108 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >